Merck's Q3 2011 earnings call highlights continued strong performance, particularly in JANUVIA, JANUMET, ISENTRESS, and GARDASIL.  Management raised the lower end of the 2011 non-GAAP EPS guidance, indicating confidence in the current trajectory of growth and cost management.  The call also emphasizes upcoming pipeline discussions on November 10th, highlighting future innovation as a key growth driver over the next 1â€“2 weeks.


1
